UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2023

C4 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-39567**	**47-5617627**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
490 Arsenal Way, Suite 120 Watertown, MA		**02472**
(Address of Principal Executive Offices)		**(Zip Code)**

Registrant's Telephone Number, Including Area Code: (617) 231-0700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CCCC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 9, 2023, C4 Therapeutics, Inc. (the "**Company**") issued a press release announcing its key milestones for 2023. A copy of the press release is furnished herewith as Exhibit 99.1.

Further, on January 9, 2023, the Company posted an investor presentation to its website at *https://ir.c4therapeutics.com/events-presentations*. A copy of the investor presentation is furnished herewith as Exhibit 99.2.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

Exhibit Number	Description
99.1	Press release issued January 9, 2023
99.2	Investor presentation of the Company dated January 2023 (furnished herewith)
104.0	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

C4 Therapeutics, Inc.

Date: January 9, 2023

By: /s/ Jolie M. Siegel

Jolie M. Siegel

Chief Legal Officer

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone

Phase 1/2 Trial of CFT8634, a BRD9 BiDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Clinical Pharmacokinetic and Pharmacodynamic Data is Supportive of Proof of Mechanism

Phase 1/2 Trial of CFT1946, a BRAF-V600 BiDAC Degrader, Initiated in Solid Tumors

Cash, Cash Equivalents and Marketable Securities of $366.0 million as of September 30, 2022; Expected to Provide Runway to End of 2024

WATERTOWN, Mass., Jan. 9, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced 2023 strategic priorities to advance its portfolio of targeted protein degradation medicines.

“In 2022, C4T progressed multiple oncology programs by initiating two clinical trials, sharing early clinical data from our lead program, and demonstrating the capabilities of our TORPEDO® platform to develop both MonoDAC and BiDAC degraders,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Based on these achievements, 2023 will be an important year with clinical data expected from our two lead programs, CFT7455 and CFT8634. We are well-resourced to execute against our strategic priorities to advance four distinct oncology programs in the clinic by the end of 2023 and deliver on the promise of targeted protein degradation science for the benefit of patients.”

RECENT ACHIEVEMENTS AND ANTICIPATED 2023 OBJECTIVES

CFT7455: CFT7455 is an oral degrader of IKZF1/3 for the treatment of multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL).

Recent Achievements:

- Progression of the ongoing Phase 1/2 clinical trial with the opening of Arm B2, evaluating CFT7455 in combination with dexamethasone for the treatment of MM.

2023 Objectives:

- Continue dose escalation in Arms B1, B2 and C of the Phase 1/2 trial, evaluating CFT7455 as a single agent in MM, in combination with dexamethasone in MM, and as a single agent in NHL, respectively.
- Present Phase 1 dose escalation data from the ongoing Phase 1/2 trial of CFT7455 in MM in the second half of 2023.

CFT8634: CFT8634 is an oral degrader of BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.

Recent Achievements:

- Pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial escalation cohorts of the ongoing CFT8634 Phase 1/2 trial demonstrate dose proportional exposure, strong oral bioavailability and deep BRD9 degradation.

2023 Objectives:

- Continue dose escalation of the CFT8634 Phase 1/2 trial in synovial sarcoma and SMARCB1-null solid tumors.
- Present Phase 1 dose escalation data from the ongoing CFT8634 Phase 1/2 trial in the second half of 2023.

CFT1946: CFT1946 is an oral degrader targeting BRAF-V600 mutations for the treatment of solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer and melanoma.

Recent Achievements:

- Initiated the Phase 1/2 trial of CFT1946 for the treatment of BRAF-V600 mutant cancers including NSCLC, colorectal cancer and melanoma.

2023 Objectives:

- Advance the dose escalation portion of the CFT1946 Phase 1/2 trial in BRAF-V600 mutant solid tumors.
- Present new preclinical data on the discovery and characterization of CFT1946 as a potent, selective, and orally bioavailable degrader for the treatment of BRAF-V600-driven cancers at a medical meeting in the first half of 2023.

CFT8919: CFT8919 is a potent and selective oral degrader of EGFR L858R for the treatment of NSCLC.

Recent Achievements:

- Completed investigational new drug (IND) enabling activities for CFT8919.

2023 Objectives:

- Submit an IND application for CFT8919 for the treatment of NSCLC in the first half of 2023.

CASH GUIDANCE

The company expects that its cash, cash equivalents and marketable securities as of September 30, 2022, together with anticipated collaboration expense reimbursements, but excluding any collaboration option or milestone payments, will enable the company to fund its operating plan to the end of 2024.

JP MORGAN PRESENTATION

C4T will present at the 41st Annual J.P. Morgan Healthcare Conference today, January 9, at 10:30 am PST (1:30 pm EST). A live webcast will be available under "Events & Presentations" in the Investors section of the company's website at www.c4therapeutics.com.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines

that transforms patients' lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com.

About CFT7455

CFT7455 is an orally bioavailable MonoDAC™ degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3). CFT7455 binds with high affinity to the E3 ligase adapter protein, cereblon, to target and degrade IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin's lymphomas, including peripheral T cell lymphoma and mantle cell lymphoma. In early clinical data, CFT7455 demonstrated deep and durable degradation of IKZF1/3. C4T is enrolling patients in its ongoing Phase 1/2 clinical trial of CFT7455. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).

About CFT8634

CFT8634 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRD9. BRD9 was previously considered an undruggable target due to the inability of bromodomain inhibitors to effectively treat cancers dependent on BRD9. Unlike BRD9 inhibition, BRD9 degradation has been shown to be efficacious in pre-clinical models of synovial sarcoma. C4T is enrolling patients in its ongoing Phase 1/2 clinical trial of CFT8634 for the treatment of synovial sarcoma and SMARCB1-null solid tumors. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05355753).

About CFT1946

CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF-V600 mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF-V600E-driven disease and in models resistant to BRAF inhibitors. C4T is advancing CFT1946 to the clinic to study treatment for BRAF-V600 mutant solid tumors including non-small cell lung cancer, colorectal cancer, and melanoma. C4T is enrolling patients in its ongoing Phase 1/2 clinical trial of CFT1946. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).

Forward-Looking Statements

This press release contains "forward-looking statements" of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our pre-clinical studies and clinical trials, including the potential timing for regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; regulatory developments in the United States and foreign countries; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual

results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of pre-clinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of pre-clinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in C4 Therapeutics' most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.

Investor Contact:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com

Media Contact:
Loraine Spreen
Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

C4 Therapeutics

Protein degraded.
Disease targeted.
Lives transformed.

January 2023

C4 Therapeutics

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward-looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.

C4T is a Leader in Delivering on the Promise of Targeted Protein Degradation

Our Mission

To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients' lives



WORLD-CLASS DEGRADER PLATFORM

Demonstrated ability to design **orally bioavailable, catalytically efficient degraders** that maximize the benefits of degradation

RIGOROUS TARGET SELECTION

Focus on targets with a **clear degrader rationale**

BROAD DEGRADER APPROACH

Only company with both **MonoDAC and BiDAC degraders** in the clinic

ROBUST CLINICAL PIPELINE

4 oncology degraders against targets of high unmet need

Focused Research and Development Strategy to Create New Medicines that Transform Patients' Lives

Progress multiple small molecule oral oncology degraders in the clinic

3 Programs currently in the clinic

1 Additional program to enter the clinic by end of 2023

Advance the next wave of research targets for difficult-to-drug and classically undruggable targets

Robust internal discovery pipeline including **7** new oncology research programs

Expand the application of the TORPEDO platform through existing and new collaboration partners

Biogen Roche Calico

C4 Therapeutics

Achievements in 2022 Position C4T for Success in 2023

	2022	2023
Progress multiple small molecule oral oncology degraders in the clinic	✓ Progressed lead clinical program, CFT7455 ✓ Initiated two new clinical trials, CFT8634 and CFT1946	❑ Present Phase 1 dose escalation data from the Phase 1/2 trials of CFT7455 and CFT8634 ❑ Advance earlier stage programs, CFT1946 and CFT8919
Expand the application of the TORPEDO platform	✓ Presented new clinical and preclinical data across three oncology programs ✓ Unveiled diverse MonoDAC chemical library	❑ Validate capability to drug previously undruggable targets ❑ Demonstrate viability of BiDAC approach
Advance the next wave of research targets	✓ Initiated research activities for seven new oncology targets	❑ Progress partnership strategy to maximize therapeutic applications of TPD ❑ Continue to leverage research and discovery to develop the next wave of targets

Two clinical readouts in 2023 **position C4T for a transformative year**

TORPEDO Platform Delivers MonoDAC and BiDAC Degraders against a Diverse Array of Target Types

MonoDAC and BiDAC Projects Initiated[1]	Projects successfully transitioned to hit identifcation[1]	Late lead optimization[1]
50 Targets evaluated across diverse cellular protein classes	**30** Cereblon-mediated degrader hit series identified	**11** Programs with series containing developable molecules

Compounds progressing based on **degrader rationale, market opportunity, and technical capability**

4 Clinical programs expected by end of 2023

- **Differentiated in vivo efficacy with achievable human doses**
- **Oral bioavailability**
- **Selectivity to desired target**
- **Cross-species PK profile to support human dose estimation**
- **CNS penetration when desired**

C4 Therapeutics

1. Number of projects initiated, hits identified, and programs are as of December 2022
Pharmacokinetic (PK); Central Nervous System (CNS)

Robust Pipeline of Wholly Owned Degrader Medicines Pursuing Multiple Targets in Oncology

Program	Target	Indications
CFT7455	**IKZF1/3**	Multiple Myeloma & Non-Hodgkin's Lymphoma
CFT8634	**BRD9**	Synovial Sarcoma & SMARCB1-Null Cancers
CFT1946	**BRAF V600**	V600 Mutant Cancers
CFT8919	**EGFR L858R**	Non-Small Cell Lung Cancer
Chromatin Regulating Targets		Various Cancers
Oncogenic Signaling Targets		Various Cancers
Transcription Factor Targets		Various Cancers



CFT7455

Targeting IKZF1/3

Multiple Myeloma (MM)
& Non-Hodgkin's Lymphoma (NHL)

C4 Therapeutics

Establish CFT7455 as a Standard of Care IKZF1/3 Degrader

Currently approved IKZF1/3 degraders (lenalidomide, pomalidomide) **are suboptimal for multiple myeloma:**	CFT7455 has the potential to **become a backbone therapy for multiple myeloma:**
Not optimally designed →	Class-leading **catalytic activity** to enable potent, rapid, and deep target degradation
Feature **off-target toxicities** →	Selective to **reduce off-target** liabilities
Resistance mechanisms develop →	High binding affinity to **overcome resistance** to currently approved IKZF1/3 degraders
Limited efficacy and **requires dosing with dexamethasone** →	Potency and PK profile provide **path to differentiated efficacy**

Approved IZKF1/3 Degrader Market is $13B[1]

C4 Therapeutics

Source:
1. 2022 Market size from EvaluatePharma

Single Agent CFT7455 Arm A Data Demonstrated Potent On Target Degradation; Dosing Schedule Modified to Improve Therapeutic Index

Deep Degradation of IKZF1/3



Meaningful Reductions in dFLC



Grade 4 Neutropenia



Modified Dosing Schedule with 14 Days Off



C4 Therapeutics

Source: C4T data on file; AACR 2022
Difference of serum free light chain (dFLC)

Phase 1/2 Trial Progressing through Dose Escalation; Safety Data and Enrollment Strategy Supported Opening of Dexamethasone Combination Arm



Phase 1 Dose Escalation Data for Multiple Myeloma Expected 2H 2023

1. 28-day cycle /7 days off dose limiting toxicity (DLT) window
2. Combination therapy arms will open once the selected CFT7455 dose level has been cleared for safety
6–12 patient food effect enrichment arm also included during escalation, not pictured in schema

Multiple Paths to Success for CFT7455 across Evolving Multiple Myeloma Landscape

Potential for CFT7455 to replace other IKFZ1/3 degraders and become a backbone therapy

IKZF1/3 degrader competitive landscape



CFT7455, as one molecule, has the potential to be utilized across all lines of therapy with or without dexamethasone

Potential to combine CFT7455 with next-generation therapies

Bi-specific T-Cell Engagers	CAR T-Cell Therapies
Antibody-Drug Conjugates	BCMA-CD38
Monoclonal Antibodies	Small Molecule Inhibitors/ Modulators

CFT8634

Targeting BRD9

Synovial Sarcoma & SMARCB1-Null Solid Tumors

C4 Therapeutics

BRD9 was Previously Considered an Undruggable Target where Inhibitors are Ineffective for Synovial Sarcoma

Unmet Need

No approved therapies specifically for synovial sarcoma

Current treatment options offer limited benefit:

- **PFS of ~7 months**[1] in the front-line setting
- **PFS ~5 months**[2] in the relapsed refractory setting

Key Properties of CFT8634

- Orally bioavailable
- Potent
- Selective

Degrader Rationale

Oncogenicity of BRD9 depends on protein function not addressed by traditional inhibitors



C4 Therapeutics

Sources:
1. Wang BC, et al. *Front Oncol.* 2021;11:76228.
2. Sleijfer S, et al. J Clin Oncol. 2009;27(19):3126-3132.

Progression Free Survival (PFS)

CFT8634 Demonstrated Deep Degradation and Robust Responses in Preclinical Synovial Sarcoma Models

PDX 310
Near Complete BRD9 Degradation



PDX SA13412
Durable Tumor Regression



C4 Therapeutics

Source: C4T data on file; AACR 2022
By mouth (PO); Once daily (QD); Pharmacodynamics (PD); Twice daily (BID); Three times daily (TID)

CFT8634 Phase 1/2 Trial Progressing through Dose Escalation



Phase1 Dose Escalation Data Expected 2H 2023

CFT8634 Pharmacokinetic and Pharmacodynamic Data Supportive of Proof of Mechanism

Dose-proportional Exposure with Strong Oral Bioavailability



Robust BRD9 Degradation in Tumor Samples



Effective Degradation of a Previously Undruggable Target

Recent Publications Support Potential Additional Indications for BRD9



Interferonopathies

BRD9 is a druggable component of interferon-stimulated gene expression and antiviral activity

EMBOpress

Interferonopathies

BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4

PNAS

Ovarian Cancer

The bromodomain containing protein BRD-9 orchestrates RAD51–RAD54 complex formation and regulates homologous recombination-mediated repair

Nature Communications

Clear Cell Renal Cell Carcinoma

Aberrant activation of m6A demethylase FTO renders HIF2a$^{low/-}$ clear cell renal cell carcinoma sensitive to BRD9 inhibitors

Science Translational Medicine

Prostate Cancer

BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression

AACR Journals

Multiple Myeloma

BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells

ASH Annual Meeting 2022

Currently Evaluating Opportunities for Indication Expansion

CFT1946

Targeting BRAF-V600

Melanoma, Colorectal (CRC)
& Non-Small Cell Lung Cancer (NSCLC)

C4 Therapeutics

Current Standard of Care BRAF Inhibitors Lead to Resistance

Unmet Need

Resistance to approved BRAF inhibitors results **in a median PFS of less than 15 months**[2]

Toxicity associated with inhibiting wild-type BRAF

~$2B approved BRAF inhibitor market[1]

Key Properties of CFT1946

- Orally bioavailable
- Potent and selective against BRAF-V600 mutant targets while sparing wild-type activity
- Preclinical activity in setting of resistance to BRAF inhibitors

Degrader Rationale



C4 Therapeutics

Sources:
1. 2022 Market size from EvaluatePharma.
2. NIH SEER Database, Primary Literature Consensus. https://www.ncbi.nlm.nih.gov/pmc/articles/MC5931274/, https://pubmed.ncbi.nlm.nih.gov/26980021/

CFT1946 Shows Superior Efficacy Compared to Approved BRAF Inhibitor in Preclinical Models

CFT1946 Shows More Durable Efficacy than Encorafenib



Combination Treatment of BRAFi Resistant Xenograft Model with CFT1946 and MEKi Shows Tumor Growth Inhibition/Regression



Source: C4T data on file; AACR 2022

BRAF inhibitor (BRAFi); MEK inhibitor (MEKi); By mouth (PO); Pharmacokinetics/pharmacodynamics (PK/PD); Once daily (QD); Twice daily (BID

CFT1946 is the First Clinical BRAF-V600 Degrader



Phase 1/2 Trial Initiated; Advance the Dose Escalation Portion of the Phase 1/2 trial

C4 Therapeutics

1. 28-day cycle/ dose limiting toxicity (DLT) window

Colorectal cancer (CRC); Recommended Phase 2 dose (RP2D); Non-Small Cell Lung Cancer (NSCLC)

CFT1946 Has the Potential to Address Multiple Tumor Types with BRAF-V600 Mutations

1.9M Cancer Diagnoses Each Year in the United States[1]

BRAF Mutations Occur in ~5% of All Cancers[2]

~100K annual incidence of BRAF mutated cancers[1]

~70-90% of BRAF mutations are V600

35% Late-stage Melanoma[2]

1-2% Non-Small Cell Lung Cancer[3]

5-10% Colorectal Cancer[4]

Sources:
1. ACS Figures & Facts 2022: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html
2. Owsley J, et al. *Experimental Biology and Medicine*. 2021;246(1):31-39
3. Paik, P. K.,, et al. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011; 29(15), 2046–2051.
4. Bylsma, L. C., et al. *Cancer medicine*.2020;9(3), 1044–1057.

CFT8919

Targeting EGFR L858R

EGFR L858R + Non-Small Cell Lung Cancer (NSCLC)

C4 Therapeutics

Potential for CFT8919 to Improve Outcomes for NSCLC Patients with EGFR L858R Mutations

Unmet Need

L858R activating mutation → **25–45%** mEGFR NSCLC

~$6B approved EGFR inhibitor market[3]

Osimertinib and other inhibitors provide suboptimal response for NSCLC patients with L858R mutation

- OSI **14.4 months** (L858R)
- OSI **21.4 months** (Exon 19 deletion)

Key Properties of CFT8919

- Orally bioavailable
- Potent and selective against L858R, regardless of secondary mutations
- Allosteric binding

Degrader Rationale



Sources:
1. Zhang, Y.-L. et al. *Oncotarget* 7, 78985–78993 (2016); Li, K et al. *Oncol Rep* 37, 1347–1358 (2017); Shin, D.-Y. et al. *J Thorac Oncol* 9, 195–199 (2014); Rangachari, D. et al. Lung Cancer 88, 108-111 (2015); Jin Y. et al. Scientific Reports 6:31636 (2016); Soria, J.-C. et al. NEJM 378, 113–125 (2018)
2. Soria, J.-C. et al. NEJM 378, 113–125 (2018), Sher, T. et al, *Mayo Clin. Proc.* 83, 355-367 (2008), NIH SEER Database 2020, Primary Literature Consensus
3. 2022 market size from EvaluatePharma.

Mutant EGFR (mEGFR); Non-small cell lung cancer (NSCLC); Tryosine Kinase Inhibitor (TKI)

CFT8919 is Selective for EGFR L858R and Active in a Setting of Osimertinib Resistance in Preclinical Models

Specific for EGFR Exon 21 Mutants



Active in setting of EGFR C797S



Submit IND application 1H 2023

C4 Therapeutics

Source: C4T data on file; Keystone Symposium 2021
Investigational New Drug Application (IND)

C4T is a Leader in Delivering on the Promise of Targeted Protein Degradation

Our Mission

To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients' lives



WORLD-CLASS DEGRADER PLATFORM

Demonstrated ability to design **orally bioavailable, catalytically efficient degraders** that maximize the benefits of degradation

RIGOROUS TARGET SELECTION

Focus on targets with a **clear degrader rationale**

BROAD DEGRADER APPROACH

Only company with both **MonoDAC and BiDAC degraders** in the clinic

ROBUST CLINICAL PIPELINE

4 oncology degraders against targets of high unmet need

2023 Expected to be a Transformative Year for C4T with Two Clinical Readouts and a Fourth Program Entering Development

CFT7455 IKZF1/3	• Present Phase 1 dose escalation data from the Phase 1/2 trial **2H**
CFT8634 BRD9	• Present Phase 1 dose escalation data from the Phase 1/2 trial **2H**
CFT1946 BRAF V600	• Advance the dose escalation portion of the Phase 1/2 trial • Present new preclinical data **1H**
CFT8919 EGFR L858R	• Submit IND application **1H**

Cash runway through the end of 2024

C4 Therapeutics

Thank You!